00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market in...
23:33 , Oct 6, 2017 |  BC Extra  |  Company News

Management tracks: Impel, InGeneron

Drug delivery company Impel NeuroPharma Inc. (Seattle, Wash.) named Jon Congleton president and CEO. He was president and CEO at Nivalis Therapeutics Inc., which merged with Alpine Immune Sciences Inc. (NASDAQ:ALPN). Regenerative medicine company InGeneron Inc....
20:12 , Jul 7, 2017 |  BC Week In Review  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
18:45 , Jul 6, 2017 |  BC Week In Review  |  Financial News

Acer plans to raise $15.7M ahead of Opexa merger

On July 3, rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) said it will raise $15.7 million from a syndicate of new and existing shareholders led by TVM Capital Life Sciences. Acer is merging with...
22:11 , Jul 3, 2017 |  BC Extra  |  Company News

Acer finds public path via Opexa merger

Rare disease company Acer Therapeutics Inc. (Cambridge, Mass.) will merge with gene therapy company Opexa Therapeutics Inc. (NASDAQ:OPXA) to form a publicly traded company that will retain Acer's name. The combined company intends to submit...
07:00 , May 16, 2016 |  BC Week In Review  |  Financial News

Acer Therapeutics completes venture financing

Acer Therapeutics Inc., Cambridge, Mass.   Business: Endocrine/Metabolic   Date completed: 2016-05-09   Type: Venture financing   Raised: $8.2 million   Investors: TVM Life Science Ventures; Bukwang Pharmaceutical Co. Ltd.   ...